AVI Biopharma Inc
AVI BioPharma, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The company?s developmental stage program includes AVI-4658, which is in phase Ib stage of clinical trial for the treatment of duchenne muscular dystrophy. Its preclinical stage programs consist of AVI-6006 for the treatment of Dengue virus; and AVI- 7100 for the treatment of H1N1 influenza virus. AVI BioPharma?s programs that are authorized to enter phase I studies include AVI-6002 for the treatment of Ebola virus; and AVI-6003 for the treatment of Marburg virus. It has strategic alliance with Charley?s Fund, Inc. The company was founded in 1980 and is headquartered in Bothell, Washington.
| Synopsis: Tech Seeker Business Condition